Alzheimer’s & Parkinson’s Drug Development Summit

3 February 20265 February 2026

Massachusetts, USAHyatt Regency Boston Harbor

An industry-focused, end-to-end meeting covering neurodegenerative R&D from early discovery through late-stage clinical and regulatory strategy.

The programme is built around the latest innovation in disease-modifying approaches, lessons learned from clinical setbacks, and the rapid progress being made in biomarker development and diagnostics. Across multiple tracks and discussion formats, it’s designed to help drug developers sharpen decision-making, stress-test strategies, and connect with peers working across the neurodegeneration pipeline.

Who the audience is and how many attend

Audience

Drug development and R&D leaders from pharma and biotech working in Alzheimer’s and Parkinson’s
Discovery and preclinical scientists advancing novel targets and translational models
Clinical development, biomarker, regulatory and trial design experts
Academic KOLs, patient voices and solution providers supporting neurodegenerative R&D

Scale

Attendees: 150+
Speakers: 40
Audience mix: 85% from large pharma & biotech
Content tracks: 2 dedicated tracks

What to expect

Three days of content spanning discovery, preclinical, clinical and regulatory challenges in AD and PD drug development
Workshops, roundtables and panel discussions, plus dedicated networking time
Coverage of emerging targets and modalities beyond first-wave approaches, alongside practical discussion of endpoints and biomarker strategy
A patient-focused component for real-world insight, plus access to partners and solution providers supporting the space